DUBLIN, Nov 22, 2018 /PRNewswire/ --
The "Particle Therapy Market by Type, Products, Services, System, Cancer Type, Application - Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The particle therapy market is projected to grow from an estimated USD 865 million in 2018 to USD 1,349 million by 2023, at a CAGR of 9.3% during the forecast period.
Growth in the particle therapy market is primarily driven by factors such as the various advantages offered by particle therapy over photon therapy, growing global prevalence of cancer, increasing adoption of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.
By product, the synchrotron segment is expected to grow at the highest rate during the forecast period
Synchrotrons are used to accelerate both protons and heavy ions such as carbon and hydrogen. The growth of the synchrotrons segment is attributed to factors such as the increasing number of research activities as well as the increasing investments in the development of synchrotron facilities.
By type, proton therapy is expected to be the largest contributor to the particle therapy market
The large share of the proton therapy segment can be attributed to factors such as the high degree of precision, shorter treatment time, and reduced side-effects associated with proton therapy as compared to conventional photon therapies using X-rays. Other factors such as the increasing research activities in the field of radiation oncology using proton therapy systems, rising number of proton therapy centers, and longer equipment lifespan of proton therapy (30 years or more) in comparison to photon therapy (10 years) are expected to support the growth of this market in the coming years.
By application, treatment applications are expected to be the largest contributor to the particle therapy market
The introduction of small footprint single-room particle therapy centers is further promoting the adoption of proton therapy for the treatment of cancer in small-scale hospitals. Factors driving the growth of the treatment applications segment include the growing number of cancer patients globally, increasing government initiatives (aimed at equipping or upgrading hospitals with newer and advanced radiotherapy systems), and the increasing availability of funding for the adoption of advanced cancer treatment technologies.
Asia Pacific is expected to hold a significant share in the particle therapy market during the forecast period
The Asia Pacific is one of the major revenue generating regions in the particle therapy market. China and Japan are the major countries responsible for the high growth of this regional market owing to factors such as the increasing per capita income, improving healthcare infrastructure, and supportive government activities in these emerging countries. Furthermore, the increasing geriatric population, growing incidence of cancer, and rising acceptance of particle therapy procedures and devices are also driving the growth of this regional market.
Ion Beam Applications SA (Belgium), Varian Medical Systems, Inc. (US), and Hitachi, Ltd. (Japan) are the major players operating in the particle therapy market.
Other players in this market include Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), ProTom International, Inc. (US), Advanced Oncotherapy Plc. (UK), and Danfysik A/S (Denmark).
Hitachi, Ltd. (Japan) is one of the leading players operating in the particle therapy market. Hitachi's proton beam therapy products have been used to treat more than 16,000 patients worldwide, and the company continues to perform joint research with advanced cancer hospitals in the US. Also, the company focuses on agreements with leading research organizations to strengthen its product development capabilities in the field of particle therapy.
- In 2017, Mitsubishi Electric signed an agreement to transfer its particle therapy systems business to Hitachi and integrate into one entity. This helped Hitachi to improve its position in the proton therapy market.
- In 2017, Royal Philips (US) and Proton Partners International (UK) collaborated with IBA (Belgium) to build the first compact proton therapy system in the Middle East.
- In 2016, Provision Asia (HK) Limited and Shenzhen Hairong International Medical Development Co., Ltd. entered into a joint venture to form Provision China. This company will be an exclusive distributor of the ProNova SC360 Proton Therapy System.
Key questions addressed by the report:
- What are the growth opportunities related to the adoption of heavy ion therapy across major regions in the future?
- Emerging countries have immense opportunities for the growth and adoption of particle therapy. Will this scenario continue in the next five years?
- Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
- What are the various cancer types wherein particle therapy finds a high adoption rate?
- What are the new trends and advancements in the particle therapy market?
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Particle Therapy: Market Overview
4.2 Regional Analysis: Particle Therapy Market, By Product & Service
4.3 Particle Therapy Market Size, By Type
4.4 Particle Therapy Market Size, By Cancer Type
4.5 Regional Analysis: Particle Therapy Market, By Application
4.6 Particle Therapy Market, By Region
5 Market Overview
5.2 Market Dynamics
220.127.116.11 Advantages Offered By Particle Therapy Over Photon Therapy
18.104.22.168 Growing Global Prevalence of Cancer
22.214.171.124 Growing Adoption of Particle Therapy in Clinical Trials
126.96.36.199 Increasing Number of Particle Therapy Centers Worldwide
188.8.131.52 Infrastructural Challenges in Healthcare Facilities
184.108.40.206 Affordability and Accessibility of Treatments
220.127.116.11 Unfavorable Reimbursement Policies and Limited Insurance Coverage for Particle Therapy
18.104.22.168 Emerging Markets
5.2.4 Industry Trends
22.214.171.124 Growing Adoption of Pencil-Beam Scanning
6 Particle Therapy Market, By Type
6.2 Proton Therapy
6.2.1 Proton Therapy is Increasingly Being Adopted as A Primary Treatment Mode for Various Cancer Types
6.3 Heavy Ion Therapy
6.3.1 The Use of Heavy Ion Therapy is Still in the Experimental Phase Across Many Regions
7 Particle Therapy Market, By Product & Service
126.96.36.199 Leading Players in the Particle Therapy Market Mainly Manufacture Cyclotrons
188.8.131.52 Increasing Investments Into the Development of Synchrotron Facilities are Contributing to Market Growth
184.108.40.206 The High Space Requirements of Synchrocyclotrons are Limiting Their Widespread Adoption
8 Particle Therapy Market, By System
8.2 Multi-Room Systems
8.2.1 Lower Shielding Requirements and Faster Beam-Switching Capabilities of Multi-Room Systems are Increasing Interest Among End Users
8.3 Single-Room Systems
8.3.1 Compact Structure and Reduced Capital Costs are Leading to High Growth of Single-Room Systems
9 Particle Therapy Market, By Cancer Type
9.1.1 Pediatric Cancer
220.127.116.11 Better Control of Radiation With Particle Therapy Makes It the Most Suitable Treatment Mode for Pediatric Cancer
9.1.2 Prostate Cancer
18.104.22.168 Particle Therapy Offers A Minimally Invasive Alternative With Increased Accuracy for Prostate Cancer Treatment
9.1.3 Lung Cancer
22.214.171.124 Rising Number of Clinical Trials to Optimize the Use of Particle Therapy for Lung Cancer is Driving the Growth of the Market
9.1.4 Breast Cancer
126.96.36.199 Limited Radiation Exposure With Reduced Side-Effects is Increasing the Adoption of Particle Therapy for Breast Cancer
9.1.5 Head and Neck Cancer
188.8.131.52 The Use of Pencil-Beam Scanning for Proton Therapy Supports Market Growth for This Segment
9.1.6 Other Cancers
10 Particle Therapy Market, By Application
10.2 Treatment Applications
10.2.1 Introduction of Small Footprint Single-Room Particle Therapy Centres is Promoting the Adoption of Particle Therapy for Cancer Treatment
10.3 Research Applications
10.3.1 Increasing Availability of Funding for Particle Therapy-Related Research Projects is Providing Growth Opportunities in Research Applications
11 Particle Therapy Market, By Region
11.2 North America
184.108.40.206 Growing Number of Particle Therapy Centers in the US to Drive Market Growth
220.127.116.11 Canadian Government Undertaking Initiatives to Include Particle Therapy as A Treatment Method
18.104.22.168 Increasing Healthcare Expenditure in France is Supporting the Adoption of Particle Therapy Products
22.214.171.124 Increasing Research in the Field of Proton & Heavy Ion Therapy to Drive the Growth of the Particle Therapy Market in Germany
126.96.36.199 Cyclotrons Segment Dominated the Particle Therapy Market in the UK
11.3.4 Rest of Europe
11.4 Asia Pacific
188.8.131.52 Japan is the Largest User of Heavy Ion Therapy for the Treatment of Various Types of Cancers
184.108.40.206 Growing Interest of Major Market Players to Increase Their Presence in China Will Drive the Growth of the Particle Therapy Market in the Country
220.127.116.11 Leading Product Manufacturers are Entering the Indian Particle Therapy Market Owing to the High Growth Opportunities in the Country
11.4.4 Rest of Asia Pacific
11.5 Rest of the World
11.5.1 Inadequate Healthcare Infrastructure is Restraining the Widespread Adoption of Particle Therapy in the Region
12 Competitive Landscape
12.2 Market Share Analysis
12.3 Competitive Scenario
12.3.1 Product Launches and Approvals
12.3.4 Agreements and Collaborations
13 Company Profiles
- Advanced Oncotherapy PLC.
- Danfysik A/S
- Hitachi, Ltd.
- Ion Beam Applications Sa (IBA)
- Mevion Medical Systems, Inc.
- Optivus Proton Therapy, Inc.
- Protom International, Inc.
- Provision Healthcare, LLC
- Sumitomo Heavy Industries, Ltd.
- Varian Medical Systems, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/cqwl7m/global_particle?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets